Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

NEW YORK, March 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024

http://www.reportlinker.com/p02041939/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

New study shows you commercial prospects for leading eye drug producersWhat does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.Our 235 page report provides 152 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. We analyse the 38 leading companies for eye medicines, to help you see the future of that industry and market. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:- Professor David T. Shima, PhD, Institute of Ophthalmology, University College London- Sean Ainsworth, CEO and Founder, RetroSense Therapeutics- Philip G. Ralston, Jr., CEO, MacuCLEAR- Dr. Michael Stewart, Associate Professor, Mayo Clinic- Authority from a company in the industry (views provided anonymously)

Discover forecasts and discussions to help you stay ahead in knowledge

You will find revenue forecasts to 2024 for nine companies, 31 top drugs and the industry, with growth rates and market shares. Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections further highlight what you will find in our report.See prospects for leading US manufacturers

Our report provides you with profiles and analyses for top companies based in the US:

• Allergan• Merck• Pfizer• RegeneronThere you examine products, progress, results, R&D pipelines and companies' revenue potentials to 2024. Also, you find sales forecasts for brands such as Restasis, Lumigan, Eylea, Combigan and Cosopt.You can assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you will find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).

What are the outlooks for leading European producers?

Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:• Novartis• RocheYou find outlooks to 2024, including revenue forecasting, as well as R&D and commercial drivers and restraints. Also, you discover sales forecasting for brands such as Lucentis, Avastin, Azopt, Vigamox and Jetrea. We show where sales growth can occur.What are the prospects for companies based in the Asia-Pacific region?You see outlooks for top companies developing and producing ocular drugs based in the Asia-Pacific region. Assess product portfolios, other activities and revenue predictions to 2024:• Santen• Senju• ValeantYou find sales prospects for brands such as Hyalein, Tapros/Taflotan, Cravit, and Diquas, along with R&D, strategies and driving and restraining forces from 2014 onwards.

Who are the leading emerging companies worldwide?

Our study also covers 29 other companies following after the world leaders. You discover activities of organisations including the following:• Abbott• Acucela• Aerie Pharmaceuticals• Aerpio Therapeutics• Akorn• Alimera Sciences• Altheos• Amakem• Ampio Pharmaceuticals• Bayer• BioDiem• Can-Fite BioPharma/OphthaliX• Chengdu Kanghong Pharmaceutical• Colby Pharmaceutical• Eleven Biotherapeutics• EyeGate Pharmaceuticals• Gene Signal• Icon Bioscience• Lpath• MacuCLEAR• Neurotech• Omeros• Ophthotech• Otsuka Pharmaceutical• OXiGENE• RXi Pharmaceuticals• Shire• Sirnaomics• ThromboGenicsYou see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss.

You also find revenue predictions for the overall industry segment

Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2024 for five world-level submarkets (therapeutic classes):• Glaucoma• Retinal disorders• Ophthalmic allergy, inflammation and infection• Dry eye• Other agentsWe predict total ophthalmic drug revenues to reach $20.9bn in 2014. We forecast high growth there to 2024. Discover the sales potential of the world market and find its most promising segments.

How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 report helps you

In summary, our 235 page report gives you the following knowledge:• Profiles of 38 leading companies - discover product ranges, recent results, strategies and competition• Outlooks for companies in eye medicine - assess top players worldwide, seeing opportunities, business data, challenges and commercial outlooks• Forecasted ophthalmic drug revenues to 2024 for the top 9 companies - find predicted financial results for those medicines• Predicted revenues of 31 leading drugs to 2024 - see potentials of top products• Potential revenues to 2024 for the world ophthalmic drug market and 5 product categories (therapeutic classes) - find the industry's sales outlook• Review of R&D pipelines - investigate developmental trends and progress• Discussion of what stimulates and restrains companies and the market• Prospects for established firms and those seeking to enter the market• View opinions from our survey, seeing interviews with authoritiesYou will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

1. Executive Summary

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

1.4 Scope of this Report

1.5 Drugs Considered for this Report

1.6 Glossary of Terms in this Report

2. Introduction to the Ophthalmic Drugs Market

2.2 The Global Burden of Eye Disease

2.3 Ophthalmic Drugs: Market Segmentation

2.4 Glaucoma: the 'Silent Thief of Sight'

2.4.1 A Classification of Glaucoma

2.4.1.1 Primary Open-Angle Glaucoma

2.4.1.2 Acute Angle-Closure Glaucoma

2.4.1.3 Congenital Glaucoma

2.4.1.4 Secondary Glaucoma

2.4.1.5 Normal-Tension Glaucoma

2.4.1.6 Ocular Hypertension

2.4.2 Risk Factors for Glaucoma

2.4.3 Diagnosis of Glaucoma

2.4.4 Drug Treatment of Glaucoma

2.4.5 Laser Treatment and Surgery for Glaucoma

2.5 Age-Related Macular Degeneration (AMD)

2.5.1 Dry (non-exudative) AMD

2.5.2 Wet (exudative) AMD

2.5.3 Risk Factors for AMD

2.5.4 Diagnosis of AMD

2.5.5 Treatment of AMD

2.6 Diabetic Retinopathy (DR)

2.6.1 Diagnosis of Diabetic Retinopathy

2.6.2 Treatment of Diabetic Retinopathy

2.7 Ocular Allergy and Allergic Conjunctivitis

2.7.1 Diagnosis of Ocular Allergy

2.7.2 Treatment of Ocular Allergy

2.8 Ocular Inflammatory Disease

2.8.1 Treatment of Ocular Inflammatory Disease

2.9 Eye Infections

2.9.1 Treatment of Eye Infections

2.10 Dry Eye Syndrome

2.10.1 Treatment of Dry Eye Syndrome

3. Ophthalmic Drugs: World Market 2014-2024

3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024

3.3 Leading Ophthalmic Drugs

3.4 Leading Companies in the Ophthalmic Drugs Market

3.4.1 Top 25 Ophthalmic Drug Manufacturers 2014-2024

3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2014-2024

3.5.1 Glaucoma Drugs Market: Sales Forecast 2014-2024

3.5.2 Retinal Disorders Drugs Market: Sales Forecast 2014-2024

3.5.3 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2014-2024

3.5.4 Dry Eye Drugs Market: Sales Forecast 2014-2024

3.6 Changing Market Shares by Segment 2014-2024

3.7 World Ophthalmic Drugs Market: Drivers and Restraints

4. Leading US Ophthalmic Drug Manufacturers in 2012 and 2013

4.1.1 Allergan: Ophthalmic Product Portfolio

4.1.1.1 Restasis: Sales Forecast 2014-2024

4.1.1.2 Lumigan and Ganfort: Sales Forecast 2014-2024

4.1.1.3 Refresh Brand Products: Sales Forecast 2014-2024

4.1.1.4 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024

4.1.1.5 Acular: Sales Forecast 2014-2024

4.1.2 Allergan: Ophthalmic Product Pipeline

4.1.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema

4.1.2.2 Novadur (Intravitreal Brimonidine Implant)

4.1.2.3 AGN 208397 (Beclomethasone Intravitreal Injection)

4.1.2.4 Anti-VEGF DARPins (VEGF Inhibitors)

4.1.3 Allergan: Ophthalmic Revenue Forecast 2014-2024

4.1.4 Allergan: SWOT Analysis

4.2 Merck

4.2.1 Merck: Ophthalmic Product Portfolio

4.2.1.1 Trusopt: Sales Forecast 2014-2024

4.2.1.2 Zioptan: Sales Forecast 2014-2024

4.2.1.3 AzaSite (azithromycin)

4.2.2 Merck: Ophthalmic Product Pipeline

4.2.3 Merck: Revenue Forecast 2014-2024

4.2.4 Merck: Drivers and Restraints

4.3 Pfizer

4.3.1 Pfizer: Ophthalmic Product Portfolio

4.3.1.1 Xalatan/Xalacom: Sales Forecast 2014-2024

4.3.1.2 Macugen (Valeant/Pfizer)

4.3.2 Pfizer: Ophthalmic Product Pipeline

4.3.3 Pfizer: Revenue Forecast 2014-2024

4.3.4 Pfizer: SWOT Analysis

4.4 Regeneron

4.4.1 Regeneron: Ophthalmic Product Portfolio

4.4.1.1 Eylea: US Sales Forecast 2014-2024

4.4.2 Regeneron: Ophthalmic Product Pipeline

4.4.3 Regeneron: Revenue Forecast 2014-2024

4.4.4 FDA Approves Zaltrap (aflibercept)

4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements

4.4.6 Regeneron: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013

5.1.1 Novartis: Ophthalmic Product Portfolio

5.1.1.1 Lucentis (ranibizumab)

5.1.1.2 Lucentis: Non-US Sales Forecast 2014-2024

5.1.1.3 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024

5.1.1.4 Vigamox: Sales Forecast 2014-2024

5.1.1.5 Azopt: Sales Forecast 2014-2024

5.1.1.6 Jetrea: Non-US Sales Forecast 2014-2024

5.1.2 Novartis: Ophthalmic Product Pipeline

5.1.2.1 Lucentis (ranibizumab) For Myopic Choroidal Neovascularisation

5.1.2.2 Finafloxacin (MerLion Pharmaceuticals/Novartis)

5.1.2.3 AKB 9778 (Aerpio Therapeutics)

5.1.2.4 AL 78898A (Complement Factor Inhibitor, Alcon)

5.1.3 Novartis: Revenue Forecast 2014-2024

5.1.4 Novartis: SWOT Analysis

5.2 Roche

5.2.1 Roche: Ophthalmic Product Portfolio

5.2.1.1 Lucentis: US Sales Forecast 2014-2024

5.2.1.2 Avastin: Sales Forecast 2014-2024

5.2.2 Roche: Ophthalmic Product Pipeline

5.2.2.1 Lampalizumab (RG7417)

5.2.3 Roche: Revenue Forecast 2014-2024

5.2.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in 2012 and 2013

6.1.1 Santen: Ophthalmic Product Portfolio

6.1.1.1 Eylea: Japan Sales Forecast 2014-2024

6.1.1.2 Hyalein: Sales Forecast 2014-2024

6.1.1.3 Cosopt: Japan Sales Forecast 2014-2024

6.1.1.4 Tapros/Taflotan: Sales Forecast 2014-2024

6.1.1.5 Diquas: Sales Forecast 2014-2024

6.1.1.6 Cravit and Tarivid: Sales Forecast 2014-2024

6.1.2 Santen: Ophthalmic Product Pipeline

6.1.3 Santen: Revenue Forecast 2014-2024

6.1.4 Santen Acquires Novagali Pharma

6.1.5 Santen: SWOT Analysis

6.2 Senju

6.2.1 Senju: Ophthalmic Product Portfolio

6.2.2 Senju: Ophthalmic Product Pipeline

6.2.2.1 Y 39983 (SNJ 1656)

6.2.2.2 Difluprednate (SJE-2079)

6.2.3 Senju: Revenue Forecast 2014-2024

6.2.4 Senju: SWOT Analysis

6.3 Valeant

6.3.1 Valeant's Acquisition of Bausch and Lomb: Aggressive Expansion?

6.3.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals

6.3.3 Valeant: Ophthalmic Product Portfolio

6.3.3.1 Macugen (Valeant/Pfizer): A Drug in Decline

6.3.4 Valeant: Ophthalmic Product Pipeline

6.3.4.1 Latanoprostene Bunod (BOL 303259-X)

6.4.3.2 Mapracorat (BOL 303242-X)

6.3.5 Valeant: Revenue Forecast 2014-2024

6.3.6 Valeant: SWOT Analysis

7. Emerging Ophthalmic Drug Manufacturers in 2012 and 2013

7.2 Notable Terminated Drug Candidates

7.3 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy

7.4 Acucela

7.5 Aerie Pharmaceuticals

7.6 Aerpio Therapeutics: Developing AKB 9778

7.7 Akorn

7.7.1 Cosopt/Cosopt PF: Sales Forecast 2014-2024

7.7.2 AzaSite: Sales Forecast 2014-2024

7.8 Alimera Sciences

7.8.1 Iluvien: Will It Gain FDA Approval?

7.8.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD

7.9 Altheos

7.10 Amakem

7.11 Ampio Pharmaceuticals

7.12 Bayer

7.12.1 Eylea: non-US Sales Forecast 2014-2024

7.13 BioDiem

7.13.1 BDM-E: A High-Value Divestment?

7.14 Can-Fite BioPharma/OphthaliX

7.15 Chengdu Kanghong Pharmaceutical: Still Developing Conbercept?

7.16 Colby Pharmaceutical

7.16.1 CPC 551: A Potential Treatment for Geographic Atrophy in Dry AMD

7.17 Eleven Biotherapeutics

7.18 EyeGate Pharmaceuticals

7.19 Gene Signal

7.19.1 Aganirsen: Preventing Corneal Graft Rejection

7.19.2 GSK

7.19.3 Darapladib for Diabetic Macular Oedema

7.20 Icon Bioscience

7.21 Lpath

7.21.1 iSONEP: Antibodies Against Bioactive Lipids

7.22 MacuCLEAR

7.22.1 MC 1101: a Potential Therapy for Dry AMD

7.23 Neurotech

7.23.1 Renexus (NT 501) for Dry AMD

7.24 Omeros

7.25 Ophthotech

7.25.1 Fovista: A Strong Competitor for the AMD Market

7.25.2 ARC1905: Complement C5 Inhibitor

7.25.3 Has Volociximab Been Terminated?

7.26 Otsuka Pharmaceutical

7.27 OXiGENE: Developing Zybrestat for Wet AMD

7.28 RXi Pharmaceuticals: Will Bevasiranib Resume Development?

7.29 Shire

7.29.1 Jerini Ophthalmic's JSM6427 and JPE 1375 Terminated?

7.29.2 Lifitegrast (SHP606) for Dry Eye

7.29.3 Premiplex (SHP607): Preventing Retinopathy of Prematurity

7.30 Sirnaomics: Acurita (STP601) Still in Preclinical Development?

7.31 ThromboGenics

7.31.1 Jetrea (ocriplasmin)

7.31.1.1 Jetrea: US Sales Forecast 2014-2024

7.31.2 TB 403: Anti-Placental Growth Factor

8. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024

8.1.1 Rivalry Among Competitors [Medium]

8.1.2 Threat of New Entrants [Low]

8.1.3 Power of Suppliers [Low]

8.1.4 Power of Buyers [Medium]

8.1.5 Threat of Substitutes [Medium]

9. Research Interviews

David T. Shima London, UK

9.1.1 On the Role of VEGF in Retinal Disorders

9.1.2 On Candidate Molecule E10030

9.1.3 On Candidate Molecule JSM 6427

9.1.4 On New Sustained Release Formulations

9.1.5 On Delta-Notch Signalling

9.1.6 Potential Clinical Crossovers Between Ophthalmology and Oncology

9.1.7 Commercial and Clinical Possibilities in the Ophthalmology Market

9.1.8 On the Possibilities of Research into the Endothelial Fenestra

9.2 Expert Interview 2: Authority from a Company in the Industry (Views Provided Anonymously)

9.2.1 Key Unmet Needs

9.2.2 Challenges Facing the Ophthalmic Sector

9.2.3 On Current Ophthalmic Treatments and Their Effectiveness

9.2.4 On Opportunities in the Ophthalmic Sector

9.3 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, Michigan, USA

9.3.1 The Optogenetic Approach to Vision Restoration

9.3.2 Choosing Disease Targets and Delivery Vectors

9.3.3 The Regulatory Picture

9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas

9.3.5 The Next Ten Years for Gene Therapy

9.4 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA

9.4.1 MC 1101: Identifying and Treating Chiou Syndrome

9.4.2 Preventing Dry AMD Progression

9.4.3 Treating the Root Cause of Dry AMD

9.4.4 Phase 3: Endpoints and Prospects for MC 1101

9.5 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA

9.5.1 The Impact of Eylea

9.5.2 The Comparative Dosing Schedules of Eylea and Lucentis

9.5.3 Patient Transitioning to Eylea: Salvage Switching

9.5.4 Avastin after the CATT Study

9.5.5 Prospects for Eylea in Other Indications and Combinations

9.5.6 Future Possibilities in Wet AMD Treatment

10. Conclusions

10.2 The World Ophthalmic Drugs Market in 2012 and 2013

10.2.1 Leading Ophthalmic Drugs Market Segments

10.2.2 Leading Ophthalmic Drugs

10.2.3 Leading Ophthalmic Drug Manufacturers

10.3 World Ophthalmic Drugs Market Forecast 2014-2024

10.4 The Future of the Ophthalmic Drugs Market?

10.4.1 Increasing Revenue Concentration among Specialist Companies

10.4.2 The Rise of Generics

10.4.3 Small Companies Can Have a Big Impact

10.4.4 What Will Succeed in the Ophthalmic Drugs Market?

List of Tables

Table 2.1 ICD 10 Classification of Visual Impairment, 2010

Table 2.2 Drug Treatments for Glaucoma, 2013

Table 2.3 Drug Treatments for AMD, 2013

Table 2.4 Drug Treatments for Ocular Allergy, 2013

Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2013

Table 2.6 Selected Drug Treatments for Eye Infections, 2013

Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2012-2013

Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024

Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), 2012-2013

Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Net Revenue ($m), Ophthalmic Drugs Revenue ($m), Market Share (%), 2012-2013

Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2013

Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2012-2018

Table 3.7 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2018-2024

Table 3.8 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024

Table 3.9 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024

Table 3.10 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024

Table 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024

Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2012, 2018 and 2024

Table 4.1 Allergan: Overview, 2012-2013

Table 4.2 Allergan: Ophthalmic Drug Products, 2013

Table 4.3 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2002-2012

Table 4.4 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.5 Allergan: Lumigan Revenue ($m), AGR (%), CAGR(%), 2000-2012

Table 4.6 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.7 Allergan: Refresh Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.8 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.10 Allergan: Revenues ($m) and Revenue Shares (%) by Region, 2012

Table 4.11 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.12 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 4.13 Merck: Overview, 2012-2013

Table 4.14 Merck: Trusopt Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.15 Merck: Zioptan Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.16 Merck: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.17 Pfizer: Overview, 2012-2013

Table 4.18 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.19 Pfizer: Macugen Revenue ($m), AGR (%), CAGR(%), 2004-2012

Table 4.20 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.21 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 4.22 Regeneron: Overview, 2012-2013

Table 4.23 Regeneron: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.24 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 4.25 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 5.1 Novartis: Overview, 2012-2013

Table 5.2 Novartis: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.3 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.4 Novartis: Vigamox Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.5 Novartis: Azopt Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.6 Novartis: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.7 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.8 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 5.9 Roche: Overview, 2012-2013

Table 5.10 Roche: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.11 Roche: Avastin Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.12 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 5.13 Roche: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 6.1 Santen: Overview, 2012-2013

Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, 2012-2013

Table 6.3 Santen: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.4 Santen: Hyalein Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.5 Santen: Cosopt Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.7 Santen: Diquas Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.8 Santen: Cravit and Tarivid Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.9 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 6.11 Senju: Overview, 2012-2013

Table 6.12 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.13 Senju: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 6.14 Valeant: Overview, 2012-2013

Table 6.15 Valeant: Selected Products Revenue ($m), 2010-2012

Table 6.16 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 6.17 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2012-2024

Table 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 7.2 Akorn: AzaSite Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 7.3 Bayer: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024

Table 7.4 ThromboGenics: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024

List of Figures

Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2012

Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012

Figure 2.4 Classification of Glaucoma, 2013

Figure 3.1 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2012

Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2013

Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m), 2012-2024

Figure 3.4 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2013

Figure 3.5 Glaucoma Drugs Market Forecast: Revenues ($m), 2012-2024

Figure 3.6 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2012-2024

Figure 3.7 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), 2012-2024

Figure 3.8 Dry Eye Drugs Market Forecast: Revenues ($m), 2012-2024

Figure 3.9 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2018

Figure 3.10 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2024

Figure 3.11 World Ophthalmic Drugs Market: Drivers and Restraints, 2014-2024

Figure 4.1 Allergan: Restasis Revenue ($m), 2002-2012

Figure 4.2 Allergan: Restasis Revenue ($m), 2012-2024

Figure 4.3 Allergan: Lumigan Revenue ($m), 2000-2012

Figure 4.4 Allergan: Lumigan and Ganfort Revenue ($m), 2012-2024

Figure 4.5 Allergan: Refresh Revenue ($m), 2012-2024

Figure 4.6 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), 2012-2024

Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024

Figure 4.8 Allergan: Revenue Shares (%) by Region, 2012

Figure 4.9 Allergan: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 4.10 Allergan: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 4.11 Merck: Trusopt Revenue ($m), 2012-2024

Figure 4.12 Merck: Zioptan Revenue ($m), 2012-2024

Figure 4.13 Merck: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 4.14 Merck: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 4.15 Merck: Drivers and Restraints, 2014-2024

Figure 4.16 Pfizer: Xalatan/Xalacom Revenue ($m), 2012-2024

Figure 4.17 Pfizer: Macugen Revenue ($m), 2004-2012

Figure 4.18 Pfizer: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 4.19 Pfizer: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 4.20 Regeneron: Eylea Revenue ($m), 2012-2024

Figure 4.21 Regeneron: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 4.22 Regeneron: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 5.1 Novartis: Lucentis Revenue ($m), 2012-2024

Figure 5.2 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), 2012-2024

Figure 5.3 Novartis: Vigamox Revenue ($m), 2012-2024

Figure 5.4 Novartis: Azopt Revenue ($m), 2012-2024

Figure 5.5 Novartis: Jetrea Revenue ($m), 2012-2024

Figure 5.6 Novartis: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 5.7 Novartis: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 5.8 Roche: Lucentis Revenue ($m), 2012-2024

Figure 5.9 Roche: Avastin Revenue ($m), 2012-2024

Figure 5.10 Roche: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 5.11 Roche: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, 2012

Figure 6.2 Santen: Eylea Revenue ($m), 2012-2024

Figure 6.3 Santen: Hyalein Revenue ($m), 2012-2024

Figure 6.4 Santen: Cosopt Revenue ($m), 2012-2024

Figure 6.5 Santen: Tapros/Taflotan Revenue ($m), 2012-2024

Figure 6.6 Santen: Diquas Revenue ($m), 2012-2024

Figure 6.7 Santen: Cravit and Tarivid Revenue ($m), 2012-2024

Figure 6.8 Santen: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 6.9 Santen: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 6.10 Senju: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 6.11 Senju: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 6.12 Valeant: Ophthalmic Drugs Revenue ($m), 2012-2024

Figure 6.13 Valeant: Ophthalmic Drugs Market Share (%), 2012-2024

Figure 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), 2012-2024

Figure 7.2 Akorn: AzaSite Revenue ($m), 2012-2024

Figure 7.3 Alimera Sciences: Ophthalmic Drug Pipeline Progress, 2013

Figure 7.4 Bayer: Eylea Revenue ($m), 2012-2024

Figure 7.5 Gene Signal: Ophthalmic Drug Pipeline Progress, 2013

Figure 7.6 Neurotech: Ophthalmic Drug Pipeline Progress, 2013

Figure 7.7 Ophthotech: Ophthalmic Drug Pipeline Progress, 2013

Figure 7.8 Shire: Ophthalmic Drug Pipeline Progress, 2013

Figure 7.9 ThromboGenics: Jetrea Revenue ($m), 2012-2024

Figure 8.1 Porter's Five Forces Analysis of the Ophthalmic Drugs Market, 2014-2024

Figure 10.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2013

Figure 10.2 World Ophthalmic Drugs Market: Revenues ($bn), 2012-2024

Figure 10.3 Leading Ophthalmic Drugs Manufactuters: Revenues ($m), 2012-2024

Companies Listed

Abbvie

Acucela

Advanced Vision Research (acquired by Akorn)

Aerie Pharmaceuticals

Aerpio Therapeutics

Akorn Pharmaceuticals

Alcon (subsidiary of Novartis)

Alimera Sciences

Allergan

Allergro Ophthalmics

Altheos

Amakem

Ampio Pharma

Asahi Glass

AstraZeneca

Aton Pharma (acquired by Valeant)

Banyu Pharmaceutical (part of Merck)

Bausch and Lomb (subsidiary of Valeant)

Bayer

Bayer Yakuhin (Japanese subsidiary of Bayer)

BioDiem

Biogen Idec

BioInvent International

Biovail Corporation (part of Valeant)

Bristol-Myers Squibb

Can-Fite BioPharma

Chengdu Kanghong Pharmaceutical

Chiron Corportation (part of Novartis)

Chugai Pharmaceutical (part of Roche)

CIBA VISION (part of Novartis)

Ciba-Geigy (part of Novartis)

Colby Pharmaceutical Company (Colby)

CoMentis

Daiichi Sankyo

Eleven Biotherapeutics

Eli Lilly and Company (Lilly)

EyeGate Pharmaceuticals

Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)

Fougera Pharmaceuticals (acquired by Novartis)

Gene Signal

Genentech (subsidiary of Roche)

Genzyme (subsidiary of Sanofi)

Gilead Sciences

GSK

ICN Pharmaceuticals (original Valeant company)

Icon Bioscience

Inamed Corporation (subsidiary of Allergan)

InSite Vision

Inspire Pharmaceuticals (acquired by Merck)

ISTA Pharmaceuticals (part of Valeant)

Jerini AG

Jerini Ophthalmic (part of Jerini AG)

Johnson & Johnson

Kestrel Ophthalmics

Kyorin Pharmaceutical

Kyowa Hakko Kirin

LEO Pharma

Lpath

MacuCLEAR

MacuSIGHT, Inc.

MAP Pharmaceuticals (acquired by Allergan)

Meda

Medicis Corporation (acquired by Valeant)

Merck & Co. (Merck)

MerLion Pharmaceuticals

MSD K.K. (part of Merck)

Mylan Pharmaceuticals

Mystic Pharmaceuticals

Neurotech

NicOx

Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)

NovaBay Pharmaceuticals

Novagali Pharma (acquired by Santen)

Novartis

Novo (subsidiary of Novo Nordisk)

Novo Nordisk

Oakwood Laboratories

OcuSciences

Omeros

Onyx Pharmaceuticals

OphthaliX (part-owned by Can-Fite BioPharma)

Ophthotech

OPKO Health

Ora

OSI Pharmaceuticals

Othera Pharmaceuticals (acquired by Colby)

Otsuka Pharmaceutical

Oxford BioMedica

OXiGENE

Parke-Davis (subsidiary of Pfizer)

PDL BioPharma

Pfizer

Pharmacia (acquired by Pfizer)

Potentia Pharmaceuticals

Premacure

Procter & Gamble

pSivida

Quark Pharmaceuticals

Reckitt Benckiser

Regeneron

RetroSense Therapeutics

ReVision Therapeutics

Roche

RXi Pharmaceuticals

Sandoz (part of Novartis)

Sanofi

Santen Pharmaceutical Co. (Santen)

SARcode Bioscience

Schering-Plough (part of Merck)

Senju

Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)

Senju USA Inc. (subsidiary of Senju)

Shire

Sirion Therapeutics

Sirna Therapeutics

Sirnaomics

SkinMedica (subsidiary of Allergan)

Spark Therapeutics

Symphony ViDA

Takeda Pharmaceutical

Teva

The Patent Board

ThromboGenics

Upjohn (acquired by Pfizer through Pharmacia)

Valeant Pharmaceuticals

Ventana Medical Systems (acquired by Roche)

Warburg Pincus LLC

Warner-Lambert (acquired by Pfizer)

Watson Pharmaceuticals

Wyeth Pharmaceuticals (part of Pfizer)

Other Organisations Mentioned in this Report

Singapore

American Academy of Ophthalmology (AAO)

American Diabetes Association

American Society of Retina Specialists (ASRS)

Association for Research in Vision and Ophthalmology (ARVO)

Council of Europe

Emory University

European Medicines Agency (EMA)

Foundation Fighting Blindness (FFB) (US)

Health Canada

Institute of Experimental Medicine (Russia)

Institute of Ocular Pharmacology, Texas A&M (US)

Institute of Ophthalmology, University College London (UK)

Intellectual Property Appellate Board (India)

International Diabetes Federation

Internet Archive

Japan Patent Office (JPO)

Mayo Clinic

Ministry of Health, Labour and Welfare (MHLW) (Japan)

Monash University

National Eye Institute (NEI) (US)

National Health Service (NHS) (UK)

National Institute for Health and Care Excellence (NICE) (UK)

NHS Scotland

Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)

Novartis Venture Funds (NVF) (part of Novartis)

Ophthalmology External Research Unit (part of Pfizer)

Ophthrisi (GSK research unit)

Rinat (Pfizer research unit)

Texas Emerging Technology Fund

Therapeutic Goods Administration (TGA) (Australia)

Tokyo University of Science

United States Food and Drug Administration (FDA)

University of Florida

University of Kentucky

University of Melbourne

University of Michigan

US Preventive Services Task Force (USPSTF)

US Securities and Exchange Commission (SEC)

World Health Organization (WHO)

To order this report: Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024 http://www.reportlinker.com/p02041939/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker